Atransen Pharma Ltd. (“APL”) is pleased to announce that it has been selected as a supported startup in the first cohort of the Nakanoshima Qross Drug Discovery Cluster Campus Development Project, operated by the Nakanoshima Qross Foundation under Japan’s Ministry of Health, Labour and Welfare.
In addition, APL has been chosen as one of the companies under the “Overseas Ecosystem Bridge Support” program, designed to help startups accelerate global expansion through practical international support.
Background and Support Framework
The Nakanoshima Qross initiative aims to form a world-class drug discovery hub in Osaka by connecting startups, academia, pharmaceutical companies, investors, and local governments to bridge innovative science to commercialization.
As a selected company, APL will receive comprehensive support including:
-
R&D and Commercialization Support – Expert guidance on regulatory strategy, CMC, non-clinical development, and IP management
-
Facility and Infrastructure Access – Priority use of laboratories, offices, and networking spaces within the Nakanoshima Qross Campus
-
Funding and Partnership Opportunities – Access to venture capital, pharmaceutical companies, and licensing/financing platforms
-
Global Expansion Support (“Bridge Support”) – Direct connections with overseas accelerators, investors, and global pharma partners, mainly in North America and Europe
With its proprietary drug discovery platform targeting LAT1 (L-type Amino Acid Transporter 1), APL aims to further accelerate the translation of its research into clinical applications and expand its international collaborations.
Future Outlook
Leveraging these programs, Atransen will:
-
Advance joint research and incubation activities at its Osaka/Nakanoshima base
-
Deepen strategic alliances with global pharmaceutical companies and investors through the bridge support initiative
-
Prepare LAT1-based oncology programs for clinical development
-
Strengthen its global presence as a Japan-originated innovator in transporter-based drug discovery
APL remains committed to delivering transformative cancer therapies based on amino acid transporter biology and tumor metabolism research.
Contact
Atransen Pharma Ltd.
Email: admin@atransen.com
https://atransen.com